Wasim K. Bleibel

Wasim Bleibel represents pharmaceutical, biotechnology, beverage, software and energy companies in intellectual property litigation, intellectual property strategy and regulatory matters. He has significant experience representing clients in patent infringement litigation arising under the Hatch-Waxman Act and advising on related regulatory matters before the Food and Drug Administration, such as market exclusivity issues and Citizen Petitions. He also regularly advises clients on compliance with the laws and regulations enforced by the Federal Trade Commission and the Alcohol and Tobacco Tax and Trade Bureau.

Wasim also has significant experience involving patent and trademark litigation and prosecution in other areas, including mechanical engineering, chemical formulations and medical devices.

Wasim also has experience in seed and agricultural biotechnology matters representing clients from seed producers to seed dealers and distributors, seedsmen's errors and omissions insurers.

Prior to his legal career, Wasim was a senior research scientist at the University of Chicago, where he worked to identify genetic determinants contributing to a patient's sensitivity to chemotherapeutic agents. His contributions resulted in his laboratory being the first to demonstrate that drug sensitivity to chemotherapy is a heritable genetic trait and that these responses vary between and amongst populations.

Wasim’s experience includes: 

• The Regents of the University of California et al. v. The Broad Institute Inc. et al., interference number 106, 115, before the Patent Trial and Appeal Board – Representing The Broad Institute, Inc. in the second patent interference proceeding involving claims to CRISPR-CAS9 systems for use in eukaryotic cells
• Otsuka Pharmaceutical Co., Ltd. et al. v. Zydus Pharmaceuticals (USA) Inc. et al., (D. Del.) – Representing drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of major depressive disorder and schizophrenia
• In re ʼ858 Patent Litigation, (S.D. Ind.) – Representing renewable energy company in patent litigation concerning the production of clean burning ethanolGS CleanTech Corp. v. Adkins Energy LLC (N.D. Ill.) – Representing renewable energy company on contract-based claims
• Actelion Pharmaceuticals Ltd. v. Zydus Pharmaceuticals (USA) Inc., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of pulmonary arterial hypertension
• Impax Laboratories v. Zydus Pharmaceuticals (USA) Inc. et al., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of Parkinson’s disease
• Sumitomo Dainippon Pharma Co., Ltd. v. Aurobindo Pharma Ltd., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of schizophrenia, depression and depression associated with bipolar disorder
• Helsinn Healthcare S.A. v. Zydus Pharmaceuticals (USA) Inc. et al., (D.N.J. Settled) – Represented drug manufacturer in Hatch-Waxman litigation concerning injectable medication indicated for the treatment and prevention of chemotherapy-induced nausea and vomiting
• Shire Development LLC, et al. v. Zydus Pharmaceuticals (USA) Inc. et al., (D. Del.) – Represented drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of ulcerative colitis
• Feit Electric Company, Inc. v. Beacon Point Capital, LLC, ( N.D. Ill.) – Represented light bulb manufacturer Feit Electric Co., Inc., in declaratory judgment action involving a variety of electrical circuit and hardware patents
• Hawk Technology Systems, LLC v. Gold Coast Group, Ltd., (N.D. Ill. Settled) – Represented defendant in patent infringement suit involving software and method patents
• eDekka LLC v. Lovely Skin, Inc., (E.D. Tex. Settled) – Represented defendant Lovely Skin, Inc., in patent infringement action involving software patents
• Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc., (S.D.N.Y.) – Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations of opioids indicated for the treatment of pain
• Warner Chilcott Company LLC v. Zydus Pharmaceuticals (USA) Inc. et al., (D. Del. Settled) – Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of ulcerative colitis
• Depomed, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al., (D.N.J. Settled) – Represented generic drug manufacturer in Hatch-Waxman litigation concerning oral formulations indicated for the treatment of Post-Herpetic Neuralgia